In our patient, TNF inhibition with etanercept was able to reduce ongoing cutaneous pro-inflammatory cytokine signaling and likely granulysin-mediated keratinocyte cell death, potentially independent of a Class IV hypersensitivity or PD-1-mediated initiation of the TEN spectrum. The gene discussed is GNLY; the disease is toxic epidermal necrolysis.